October 4, 2024 12:28 PM EDT
R&D
Pharma

J&J dis­con­tin­ues mid-stage dengue study, cit­ing de­pri­or­i­ti­za­tion of com­mu­ni­ca­ble dis­ease work

Max Bayer

Pharma Reporter

What’s left of John­son & John­son’s in­fec­tious dis­ease work con­tin­ues to shrink, af­ter the com­pa­ny an­nounced Fri­day that it had stopped work on a mid …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times